Most patients treated with RELiZORB fall into the high-risk category of the US population for COVID-19 infection. We are confirming secure access to RELiZORB based on a current assessment of our global supply chain and do not anticipate any potential RELiZORB supply disruption in the mid-term due to the COVID-19 outbreak. We will continue to monitor the situation and take all necessary action in an effort to keep inventories high and ensure supply continuity. Know that we will keep patient advocacy organizations and health care providers informed of any material changes.